Zosano, Novo Nordisk deal

Zosano said Novo Nordisk will terminate a 2014 deal granting Novo exclusive, worldwide rights to develop and commercialize Novo’s glucagon-like peptide-1 (GLP-1) analogs using Zosano’s microneedle pa...